Stockscreener 앱 받기
25.31
10.24%
2.35
시간 외 거래:
25.40
0.09
+0.36%
전일 마감가:
$22.96
열려 있는:
$23.35
하루 거래량:
1.84M
Relative Volume:
2.17
시가총액:
$2.84B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-11.77
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
+18.94%
1개월 성능:
+26.42%
6개월 성능:
+25.36%
1년 성능:
+49.67%
1일 변동 폭
$23.23
$25.85
1주일 범위
$21.23
$25.85
52주 변동 폭
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
NAMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
25.31 | 2.65B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
Analysts Are Upgrading NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) After Its Latest Results - Yahoo Finance
Can technical indicators confirm NewAmsterdam Pharma Company N.V.’s reversalEntry Opportunity Screener with Confirmation - Newser
Comparing NewAmsterdam Pharma Company N.V. Equity Warrant in custom built stock radarsFree Trade Setups With Clear Risk Limits - Newser
Visualizing NewAmsterdam Pharma Company N.V. Equity Warrant stock with heatmapsWeekly Price Target Forecast and Alerts - Newser
Visual analytics tools that track NewAmsterdam Pharma Company N.V. performanceFree Trade Setups With Clear Risk Limits - Newser
Technical analysis overview for NewAmsterdam Pharma Company N.V. stockFree AI Driven Buy Alert Trade Blueprint - Newser
Will NewAmsterdam Pharma Company N.V. price bounce be sustainableTechnical Reversal Setup with Risk Limits - Newser
NewAmsterdam Pharma Second Quarter 2025 Earnings: US$0.15 loss per share (vs US$0.41 loss in 2Q 2024) - uk.finance.yahoo.com
NewAmsterdam Pharma earnings beat by $0.35, revenue topped estimates - Investing.com UK
NewAmsterdam Pharma Reports Q2 2025 Financial Results - TipRanks
NewAmsterdam (NAMS) Q2 Revenue Jumps 49% - The Motley Fool
Newamsterdam Pharma shares rise 6.12% intraday as Q2 net loss narrows and revenue rises. - AInvest
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates - sharewise.com
NewAmsterdam Pharma Q2 Net Loss Narrows, Revenue Rises - MarketScreener
NewAmsterdam Pharma Company NV reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (NAMS) NewAmsterdam Pharma Company N.V. Reports Q2 Revenue $19.1M, vs. FactSet Est of $1.9M - MarketScreener
Understanding NewAmsterdam Pharma Company N.V. Equity Warrant’s price movementFree Consistent Income Focused Trade List - Newser
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - GlobeNewswire
NewAmsterdam Pharma Co N.V. SEC 10-Q Report - TradingView
Is NewAmsterdam Pharma Company N.V. Equity Warrant the Top Chart Pick This WeekHigh Conviction Intraday Stock Signals Detected - beatles.ru
Published on: 2025-08-04 14:31:37 - metal.it
What is the dividend policy of NewAmsterdam Pharma Company N.V. stockInvest confidently with daily market forecasts - Jammu Links News
What drives NewAmsterdam Pharma Company N.V. stock priceExponentially increasing returns - Jammu Links News
Should I hold or sell NewAmsterdam Pharma Company N.V. stock in 2025Discover stocks with massive upside potential - Jammu Links News
Is NewAmsterdam Pharma Company N.V. Equity Warrant a growth stock or a value stockTurn market volatility into profit opportunities - Jammu Links News
What are the technical indicators suggesting about NewAmsterdam Pharma Company N.V.Build a portfolio with strong long-term growth - Jammu Links News
What are the latest earnings results for NewAmsterdam Pharma Company N.V.Accelerated wealth building - Jammu Links News
What institutional investors are buying NewAmsterdam Pharma Company N.V. Equity Warrant stockFree Technical Analysis Support - Jammu Links News
Why is NewAmsterdam Pharma Company N.V. Equity Warrant stock attracting strong analyst attentionExceptional profit margins - Jammu Links News
What are the latest earnings results for NewAmsterdam Pharma Company N.V. Equity WarrantBoost your returns with professional guidance - jammulinksnews.com
What is NewAmsterdam Pharma Company N.V. company’s growth strategyExceptional profit potential - Jammu Links News
What are NewAmsterdam Pharma Company N.V. Equity Warrant company’s key revenue driversCapitalize on emerging investment opportunities - Jammu Links News
What are NewAmsterdam Pharma Company N.V. company’s key revenue driversDiscover the fastest growing stocks today - Jammu Links News
Is it the right time to buy NewAmsterdam Pharma Company N.V. Equity Warrant stockFree Stock Market Return Analysis - Jammu Links News
Published on: 2025-08-04 00:09:00 - Jammu Links News
When is NewAmsterdam Pharma Company N.V. stock expected to show significant growthStay ahead with daily market updates - Jammu Links News
Should I hold or sell NewAmsterdam Pharma Company N.V. Equity Warrant stock in 2025Game-changing returns - Jammu Links News
What drives NewAmsterdam Pharma Company N.V. Equity Warrant stock priceTap into rapid wealth building techniques - Jammu Links News
How strong is NewAmsterdam Pharma Company N.V. Equity Warrant company’s balance sheetCapitalize on market trends with expert guidance - Jammu Links News
Published on: 2025-08-03 11:05:58 - Jammu Links News
Published on: 2025-08-03 06:39:53 - Jammu Links News
What is the risk reward ratio of investing in NewAmsterdam Pharma Company N.V. Equity Warrant stockTurn market volatility into profit opportunities - Jammu Links News
What makes NewAmsterdam Pharma Company N.V. Equity Warrant stock price move sharplyInvest smarter with data-backed insights - Jammu Links News
What are analysts’ price targets for NewAmsterdam Pharma Company N.V. in the next 12 monthsPre Market Entry Points To Watch Now - Jammu Links News
Does NewAmsterdam Pharma Company N.V. qualify in momentum factor screeningReal-Time Analysis With Entry Targets In Progress - metal.it
What institutional investors are buying NewAmsterdam Pharma Company N.V. stockRetirement Planning Guidance To Watch Now - jammulinksnews.com
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):